Methods of making DLL3 antibody drug conjugates
View Patent ↗Novel modulatators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
1. A method of making an antibody drug conjugate (ADC) of the formula M-[L-D]n, the method comprising the steps of:
(a) providing a drug D, wherein D comprises a pyrrolobenzodiazepine (PBD);
(b) providing a linker L;
(c) synthesizing a linker-PBD [L-D] conjugate;
(d) conjugating the [L-D] conjugate to M, wherein M comprises a chimeric, CDR -grafted, or humanized anti-DLL3 antibody that specifically binds to an epitope within the DSL domain of a DLL3 protein set forth as SEQ ID NO: 3 or 4, wherein the anti-DLL3 antibody is capable of internalizing upon binding to a cell expressing DLL3;
and wherein the conjugating occurs under conditions where n is an integer from 1 to 20.
2. The method of claim 1 , wherein the linker L comprises a terminal thiol reactive group.
3. The method of claim 2 , wherein the anti-DLL3 antibody comprises a reducible cysteine that can be made reactive for conjugating with the linker L.
4. The method of claim 3 , wherein the anti-DLL3 antibody and the [L-D] conjugate are conjugated by reaction of the reduced cysteine of the anti-DLL3 antibody with the terminal thiol reactive group of the linker L.
5. The method of claim 1 , further comprising the step of:
(e) purifying the ADC by ion exchange column chromatography.
6. The method of claim 1 , wherein the pyrrolobenzodiazepine (PBD) comprises the formula AC:
wherein:
the dotted lines indicate the optional presence of a double bond, and wherein only one of the dotted lines in a given ring can be a double bond;
R 2 is selected from H, OH, ═O, ═CH 2 , CN, R, OR, ═CH—R D , ═C(R D ) 2 , O—SO 2 —R, CO 2 R, COR, and halo, where R D is selected from R, CO 2 R, COR, CHO, CO 2 H, and halo;
R 6 and R 9 are each independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
R 7 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
R 10 is the linker L connected to the anti-DLL3 antibody;
Q is selected from O, S and NH;
R 11 is either H, or R or, where Q is O, SO 3 M, where M is a metal cation;
R and R′ are each independently selected from optionally substituted C 1-12 alkyl, C 3-20 heterocyclyl and C 5-20 aryl groups, and optionally in relation to the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;
X is selected from O, S, and N(H);
R 2″ , R 6″ , R 7″ , R 9″ , and X″ are as defined according to R 2 , R 6 , R 7 , R 9 , and X, respectively;
and
R″ is a C 3-12 alkylene group, which comprises a chain optionally interrupted by one or more heteroatoms, one or more rings, or both one or more heteroatoms and one or more rings, wherein the optional one or more rings are optionally substituted.
7. The method of claim 6 , wherein
(a) R 2 is R, wherein R is a C 5-20 aryl group;
(b) R 6 and R 9 are H;
(c) R 7 is OR, and wherein R is a C 1 alkyl;
(d) Q is O, and wherein R 11 is H; or
(e) X and X″ are O.
8. The method of claim 1 , wherein the ADC further comprises the structure:
wherein:
CBA is a cell binding agent, which is the anti-DLL3 antibody M;
A, L 1 , and L 2 are components of the linker L;
A is a connecting group connecting L 1 to the cell binding agent (CBA);
L 1 is optionally a cleavable linker;
L 2 is a covalent bond or together with the —OC(═O)— group forms a self-immolative linker; and
wherein the linker L is attached to the pyrrolobenzodiazepine (PBD) at the position of the asterisk (*).
9. The method of claim 8 , wherein L 1 comprises a cleavable linker and the cleavable linker comprises a dipeptide.
10. The method of claim 9 , wherein the dipeptide is Phe-Lys, Val-Ala, Val-Lys, Ala-Lys, Val-Cit, Phe-Cit, Leu-Cit, Ile-Cit, Phe-Arg, or Trp -Cit.
11. The method of claim 10 , wherein the dipeptide is Val-Ala.
12. The method of claim 11 , wherein the moiety:
comprises the structure:
wherein the wavy line indicates the point of attachment of the structure directly to A or to a remaining portion of L1 that is further connected to A.
13. The method of claim 1 , wherein
(a) the anti-DLL3 antibody specifically binds to an epitope comprising amino acids G203, R205 and P206 (SEQ ID NO: 10); or
(b) the anti-DLL3 antibody competes for binding to human DLL3 protein with an antibody comprising a light chain variable region set forth as SEQ ID NO: 84 and a heavy chain variable region set forth as SEQ ID NO: 85.
14. The method of claim 1 , wherein the anti-DLL3 antibody comprises:
(a) residues 24-34 of SEQ ID NO: 84 for CDR-L1, residues 50-56 of SEQ ID NO: 84 for CDR-L2, residues 89-97 of SEQ ID NO: 84 for CDR-L3, residues 31-35 of SEQ ID NO: 85 for CDR-H1, residues 50-65 of SEQ ID NO: 85 for CDR-H2 and residues 95-102 of SEQ ID NO: 85 for CDR-H3, wherein the residues are numbered according to Kabat; or
(b) a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 212 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 213.
15. A method of making an antibody drug conjugate (ADC) of the formula M-[L-D]n, the method comprising the steps of:
(a) providing a drug D, wherein D comprises a cytotoxic agent;
(b) providing a linker L;
(c) synthesizing a linker-cytotoxic agent [L-D] conjugate;
(d) conjugating the [L-D] conjugate to M, wherein M comprises a chimeric, CDR -grafted, or humanized anti-DLL3 antibody that specifically binds to an epitope within the DSL domain of a DLL3 protein set forth as SEQ ID NO: 3 or 4, wherein the anti-DLL3 antibody is capable of internalizing upon binding to a cell expressing DLL3;
under such conditions where n is an integer from 1 to 20.
16. The method of claim 15 , wherein the linker L comprises a terminal thiol reactive group.
17. The method of claim 16 , wherein the anti-DLL3 antibody comprises a reducible cysteine that can be made reactive for conjugating with the linker L.
18. The method of claim 17 , wherein the anti-DLL3 antibody and the [L-D] conjugate are conjugated by reaction of the reduced cysteine of the anti-DLL3 antibody with the terminal thiol reactive group of the linker L.
19. The method of claim 15 , further comprising the step of:
(e) purifying the ADC by ion exchange column chromatography.
20. The method of claim 15 , wherein the cytotoxic agent comprises a pyrrolobenzodiazepine (PBD), an auristatin, or a maytansinoid.
21. The method of claim 20 , wherein the cytotoxic agent comprises a pyrrolobenzodiazepine.
22. The method of claim 21 , wherein the cytotoxic agent comprises a pyrrolobenzodiazepine comprising the formula AC:
wherein:
the dotted lines indicate the optional presence of a double bond, and wherein only one of the dotted lines in a given ring can be a double bond;
R 2 is selected from H, OH, ═O, ═CH 2 , CN, R, OR, ═CH—R D , ═C(R D ) 2 , O—SO 2 —R, CO 2 R, COR, and halo, where R D is selected from R, CO 2 R, COR, CHO, CO 2 H, and halo;
R 6 and R 9 are each independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
R 7 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
R 10 is the linker L connected to the anti-DLL3 antibody;
Q is selected from O, S and NH;
R 11 is either H, or R or, where Q is O, SO 3 M, where M is a metal cation;
R and R′ are each independently selected from optionally substituted C 1-12 alkyl, C 3-20 heterocyclyl and C 5-20 aryl groups, and optionally in relation to the group NRR', R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;
X is selected from O, S, and N(H);
R 2″ , R6″, R 7″ , R 9″ , and X″ are as defined according to R 2 , R 6 , R 7 , R 9 , and X, respectively;
and
R″ is a C 3-12 alkylene group, which comprises a chain optionally interrupted by one or more heteroatoms, one or more rings, or both one or more heteroatoms and one or more rings, wherein the optional one or more rings are optionally substituted.
23. The method of claim 22 , wherein
(a) R 2 is R, wherein R is a C 5-20 aryl group;
(b) R 6 and R 9 are H;
(c) R 7 is OR, and wherein R is a C 1 alkyl;
(d) Q is O, and wherein R 11 is H; or
(e) X and X″ are O.
24. The method of claim 15 , wherein the ADC further comprises the structure:
wherein:
CBA is a cell binding agent, which is the anti-DLL3 antibody M;
A, L 1 , and L2 are components of the linker L;
A is a connecting group connecting L 1 to the cell binding agent (CBA);
L 1 is optionally a cleavable linker;
L 2 is a covalent bond or together with the —OC(═O)— group forms a self-immolative linker; and
wherein the linker L is attached to the pyrrolobenzodiazepine (PBD) at the position of the asterisk (*).
25. The method of claim 24 , wherein L 1 comprises a cleavable linker and the cleavable linker comprises a dipeptide.
26. The method of claim 25 , wherein the dipeptide is Phe-Lys, Val-Ala, Val-Lys, Ala-Lys, Val-Cit, Phe-Cit, Leu-Cit, Ile-Cit, Phe-Arg, or Trp -Cit.
27. The method of claim 26 , wherein the dipeptide is Val-Ala.
28. The method of claim 27 , wherein the moiety:
comprises the structure:
wherein the wavy line indicates the point of attachment of the structure directly to A or to a remaining portion of L1 that is further connected to A.
29. The antibody drug conjugate of claim 15 , wherein
(a) the anti-DLL3 antibody specifically binds to an epitope comprising amino acids G203, R205 and P206 (SEQ ID NO: 10); or
(b) the anti-DLL3 antibody competes for binding to human DLL3 protein with an antibody comprising a light chain variable region set forth as SEQ ID NO: 84 and a heavy chain variable region set forth as SEQ ID NO: 85.
30. The method of claim 15 , wherein the anti-DLL3 antibody comprises:
(a) residues 24-34 of SEQ ID NO: 84 for CDR-L1, residues 50-56 of SEQ ID NO: 84 for CDR-L2, residues 89-97 of SEQ ID NO: 84 for CDR-L3, residues 31-35 of SEQ ID NO: 85 for CDR-H1, residues 50-65 of SEQ ID NO: 85 for CDR-H2 and residues 95-102 of SEQ ID NO: 85 for CDR-H3, wherein the residues are numbered according to Kabat; or
(b) a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 212 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 213.